PE20050480A1 - Acido [2-(8,9-dioxo-2,6-diazabiciclo [5.2.0] non-1(7)-en-2-il)alquil]fosfonico y derivados - Google Patents

Acido [2-(8,9-dioxo-2,6-diazabiciclo [5.2.0] non-1(7)-en-2-il)alquil]fosfonico y derivados

Info

Publication number
PE20050480A1
PE20050480A1 PE2004001002A PE2004001002A PE20050480A1 PE 20050480 A1 PE20050480 A1 PE 20050480A1 PE 2004001002 A PE2004001002 A PE 2004001002A PE 2004001002 A PE2004001002 A PE 2004001002A PE 20050480 A1 PE20050480 A1 PE 20050480A1
Authority
PE
Peru
Prior art keywords
dioxo
alkyl
diazabicyclo
derivatives
phosphonic acid
Prior art date
Application number
PE2004001002A
Other languages
English (en)
Spanish (es)
Inventor
Eric J Benjamin
Mohammed Islam
William F Cloud
Michael R Brandt
Muhammad Ashraf
Gerald F Tremblay
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PE20050480A1 publication Critical patent/PE20050480A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PE2004001002A 2003-10-15 2004-10-15 Acido [2-(8,9-dioxo-2,6-diazabiciclo [5.2.0] non-1(7)-en-2-il)alquil]fosfonico y derivados PE20050480A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51156003P 2003-10-15 2003-10-15
US10/961,871 US20050142192A1 (en) 2003-10-15 2004-10-08 Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives

Publications (1)

Publication Number Publication Date
PE20050480A1 true PE20050480A1 (es) 2005-10-24

Family

ID=34704145

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004001002A PE20050480A1 (es) 2003-10-15 2004-10-15 Acido [2-(8,9-dioxo-2,6-diazabiciclo [5.2.0] non-1(7)-en-2-il)alquil]fosfonico y derivados

Country Status (13)

Country Link
US (1) US20050142192A1 (enExample)
EP (1) EP1682151A1 (enExample)
JP (1) JP2007509055A (enExample)
KR (1) KR20070029114A (enExample)
AU (1) AU2004281806A1 (enExample)
BR (1) BRPI0415432A (enExample)
CA (1) CA2541402A1 (enExample)
CO (1) CO5690561A2 (enExample)
MX (1) MXPA06003982A (enExample)
PA (1) PA8614901A1 (enExample)
PE (1) PE20050480A1 (enExample)
TW (1) TW200528113A (enExample)
WO (1) WO2005037287A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1863810B (zh) * 2003-04-09 2010-12-01 惠氏公司 [2-(8，9-二氧代-2，6-二氮杂二环[5.2.0]壬-1(7)-烯-2-基)烷基]膦酸衍生物及其作为n-甲基-d-天冬氨酸(nmda)受体拮抗剂的应用
MXPA05010763A (es) * 2003-04-09 2005-12-12 Wyeth Corp Composiciones farmaceuticas para administracion intranasal de acido [2-(8, 9-dioxo-2, 6-diazabiciclo [5.2.0] non-1(7) -en-2-il) alquil- fosfonico] y metodos de uso del mismo.
TW200514775A (en) 2003-10-22 2005-05-01 Wyeth Corp Methods for the preparation of {2-[(8,9)-dioxo-2,6-diaza-bicyclo[5.2.0]-non-1(7)-en-2-yl]ethyl} phosphonic acid and esters thereof
US20050244365A1 (en) * 2004-05-03 2005-11-03 Novaflux Biosciences, Inc. Methods, compositions, formulations, and uses of cellulose and acrylic-based polymers
AU2006210572B2 (en) 2005-02-03 2011-08-04 The General Hospital Corporation Method for treating gefitinib resistant cancer
AR057854A1 (es) 2005-11-04 2007-12-19 Wyeth Corp Combinaciones antineoplasicas con inhibidor de mtor, herceptina y/o hki-272 (e)-n-{4-[3-cloro-4-(2-piridinilmetoxi) anilino]-3-ciano-7-etoxi-6-quinolinil}-4-(dimetilamino)-2-butenamida
AU2008293622A1 (en) * 2007-08-27 2009-03-05 Wyeth Llc Compositions and methods employing NMDA antagonists for achieving an anesthetic-sparing effect
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
EP2251012A4 (en) * 2008-02-11 2013-03-06 Dainippon Sumitomo Pharma Co TABLET HAVING ENHANCED ELUTING PROPERTIES
WO2010008744A2 (en) 2008-06-17 2010-01-21 Wyeth Antineoplastic combinations containing hki-272 and vinorelbine
CN102202667A (zh) 2008-08-04 2011-09-28 惠氏有限责任公司 4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合
US8771735B2 (en) * 2008-11-04 2014-07-08 Jazz Pharmaceuticals, Inc. Immediate release dosage forms of sodium oxybate
US8778398B2 (en) * 2008-11-04 2014-07-15 Jazz Pharmaceuticals, Inc. Immediate release formulations and dosage forms of gamma-hydroxybutyrate
LT3000467T (lt) 2009-04-06 2023-04-11 Wyeth Llc Krūties vėžio gydymo schema naudojant neratinibą
ES2729677T3 (es) 2009-11-09 2019-11-05 Wyeth Llc Esferoides de fármacos recubiertos y sus usos para eliminar o reducir condiciones, como la emesis y la diarrea
PT2498756T (pt) * 2009-11-09 2019-11-26 Wyeth Llc Formulações de comprimidos de maleato de neratinib
US20120076865A1 (en) 2010-03-24 2012-03-29 Jazz Pharmaceuticals, Inc. Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances
DK3932932T3 (da) * 2013-03-13 2025-08-18 Sage Therapeutics Inc Neuroaktive sterioder og fremgangsmåder til anvendelse deraf
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
ES2865258T3 (es) 2015-07-06 2021-10-15 Sage Therapeutics Inc Oxiesteroles y procedimientos de uso de los mismos
WO2017173358A1 (en) 2016-04-01 2017-10-05 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
CN113395960A (zh) 2018-11-19 2021-09-14 爵士制药爱尔兰有限公司 抗酒精药物制剂
CN119868330A (zh) 2019-03-01 2025-04-25 弗拉梅尔爱尔兰有限公司 在进食状态下具有改善的药代动力学的γ-羟基丁酸酯组合物
TW202139986A (zh) 2020-02-21 2021-11-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 治療原發性嗜睡症之方法
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5168103A (en) * 1991-01-22 1992-12-01 American Home Products Corporation [[2-(amino-3,4-dioxo-1-cyclobuten-1-yl) amino]alkyl]-acid derivatives
US5124319A (en) * 1991-10-11 1992-06-23 American Home Products Corporation Benzimidazole phosphono-amino acids
US5990307A (en) * 1997-08-01 1999-11-23 American Home Products Corporation Process for the preparation of [2-((8.9)-Dioxo-2,6-Diazabicyclo [5.2.0]-Non-1(7)-en-2yl) Ethyl]Phosphonic acid
US6225343B1 (en) * 1999-06-16 2001-05-01 Nastech Pharmaceutical Company, Inc. Compositions and methods comprising morphine gluconate
US6468559B1 (en) * 2000-04-28 2002-10-22 Lipocine, Inc. Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods
US6555581B1 (en) * 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
US20020160043A1 (en) * 2001-02-27 2002-10-31 Dennis Coleman Compositions and method of manufacture for oral dissolvable dosage forms
UA78529C2 (en) * 2001-10-10 2007-04-10 Wyeth Corp Derivatives of [[2-(amino-3,4-dioxo-1-cyclobutene-1-yl)amino]alkyl] acid for treating pain
JP4452970B2 (ja) * 2002-03-27 2010-04-21 日本臓器製薬株式会社 ジクロフェナクナトリウム経口製剤
US20040082543A1 (en) * 2002-10-29 2004-04-29 Pharmacia Corporation Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain
MXPA05010763A (es) * 2003-04-09 2005-12-12 Wyeth Corp Composiciones farmaceuticas para administracion intranasal de acido [2-(8, 9-dioxo-2, 6-diazabiciclo [5.2.0] non-1(7) -en-2-il) alquil- fosfonico] y metodos de uso del mismo.

Also Published As

Publication number Publication date
KR20070029114A (ko) 2007-03-13
CA2541402A1 (en) 2005-04-28
BRPI0415432A (pt) 2006-12-05
AU2004281806A1 (en) 2005-04-28
JP2007509055A (ja) 2007-04-12
TW200528113A (en) 2005-09-01
EP1682151A1 (en) 2006-07-26
WO2005037287A1 (en) 2005-04-28
US20050142192A1 (en) 2005-06-30
CO5690561A2 (es) 2006-10-31
WO2005037287A8 (en) 2005-06-30
MXPA06003982A (es) 2006-07-05
PA8614901A1 (es) 2006-05-16

Similar Documents

Publication Publication Date Title
PE20050480A1 (es) Acido [2-(8,9-dioxo-2,6-diazabiciclo [5.2.0] non-1(7)-en-2-il)alquil]fosfonico y derivados
RU2008123839A (ru) Соединение оксазола и фармацевтическая композиция
AR040773A1 (es) Pirazoles utiles como inhibidores de gsk-3
PE20040539A1 (es) COMPUESTOS DE AMIDAS DE ACIDO 3-AMINO-TIENO [2,3-b] PIRIDINO-2-CARBOXILICO SUSTITUIDO Y PROCEDIMIENTOS PARA PREPARARLOS
CO5251463A1 (es) Compuestos heterociclicos y composicion farmaceutica que coniene dichos compuestos
HRP20090250T1 (hr) Kondenzirani heterociklički spojevi i njihova upotreba kao inhibitora hcv polimeraze
PE20110118A1 (es) Compuestos de pirimidina amida como inhibidores de pgds
HUP0301427A2 (hu) Fotokemoterápiában alkalmazható fotoszenzitizáló, 5-aminolevulinsavészterek azokat tartalmazó gyógyszerkészítmények és alkalmazásuk
EA200100755A1 (ru) 4-оксо-1,4-дигидро-3-хинолинкарбоксамиды как антивирусные агенты
RU2007142328A (ru) Производные тиоксантина в качестве ингибиторов миелопероксидазы
PE20050484A1 (es) Composicion farmaceutica de liberacion sostenida
DE60329513D1 (de) Antagonist des melanin-concentrating-hormone-rezeptors, enthaltend ein benzimidazolderivat als wirkstoff
JP2005504729A5 (enExample)
HRP20080493T3 (hr) Supstituirani kinolinski derivati kao mitotski inhibitori kinezina
PE55298A1 (es) Derivados de pirrolopirrolona
PT1157998E (pt) Compostos heterociclicos seus intermediarios e inibidores da elastase
DE60003435D1 (de) Neue 2-decarboxy-2-phosphinico prostaglandin f analoge
WO2002078615A3 (en) Antioxidant nitroxides and nitrones as therapeutic agents
PE58899A1 (es) Esteres y amidas de fenil xantina
PE20010300A1 (es) Preparacion de piperidin-4-onas sustituidas
PE20060630A1 (es) Amidas sustituidas de acido tienopirrolcarboxilico, amidas del acido pirrolotiazolcarboxilico y analogos relacionados como inhibidores de la caseina cinasa ie
MA33103B1 (fr) Derives de 6-(6-substitue-triazolopyridazine-sulfanyl) 5-fluoro-benzothiazoles et 5-fluoro-benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met
ATE37872T1 (de) Phenylinden-derivate, ihre salze, und verfahren zu ihrer herstellung.
ATE149494T1 (de) Benzopyranderivate und verfahren zu deren herstellung
ATE212637T1 (de) Anitbiotisch wirksame cephalosporine und verfahren zu ihrer herstellung

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed